Latest filings (excl ownership)
15-12G
Securities registration termination
26 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Mar 24
EFFECT
Notice of effectiveness
16 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
POS AM
Prospectus update (post-effective amendment)
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Other Events
2 Jan 24
25-NSE
Exchange delisting
27 Dec 23
8-K
Impel Pharmaceuticals Announces Filing Voluntary Chapter 11 Cases and Signing of “Stalking Horse” Agreement to Facilitate Sale
20 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
10-Q
2024 Q3
Quarterly report
14 Nov 23
8-K
Departure of Directors or Certain Officers
14 Nov 23
8-K
Departure of Directors or Certain Officers
2 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Oct 23
424B5
Prospectus supplement for primary offering
5 Oct 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
8-K
Regulation FD Disclosure
18 Sep 23
8-K
Entry into a Material Definitive Agreement
7 Sep 23
8-K
Entry into a Material Definitive Agreement
21 Aug 23
10-Q
2024 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
12 May 23
8-K
Departure of Directors or Certain Officers
10 May 23
ARS
2023 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Departure of Directors or Certain Officers
12 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Mar 23
10-K/A
2022 FY
Annual report (amended)
31 Mar 23
S-8
Registration of securities for employees
27 Mar 23
10-K
2022 FY
Annual report
27 Mar 23
8-K
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
24 Mar 23
8-K
Departure of Directors or Certain Officers
3 Mar 23
Latest ownership filings
4
Diane E. Wilfong
9 Apr 24
4
TIMOTHY S NELSON
9 Apr 24
4
David D. Allison
9 Apr 24
3
Brandon D Smith
26 Dec 23
4
Change in insider ownership
19 Dec 23
4
Asset Management ULC Brookfield
4 Dec 23
4
Change in insider ownership
4 Dec 23
4
Change in insider ownership
4 Dec 23
SC 13D/A
Oaktree Capital Group, LLC
4 Dec 23
3
Asset Management ULC Brookfield
20 Nov 23
3
Initial statement of insider ownership
20 Nov 23
3
Initial statement of insider ownership
20 Nov 23
SC 13D/A
Oaktree Capital Group, LLC
15 Nov 23
SC 13D/A
Oaktree Capital Group, LLC
6 Oct 23
SC 13D
Oaktree Capital Group, LLC
15 Sep 23
4
Darren S Cline
20 Jun 23
4
Diane E. Wilfong
20 Jun 23
4
MAHENDRA SHAH
20 Jun 23
4
TIMOTHY S NELSON
20 Jun 23
4
David D. Allison
20 Jun 23
4
Michael Wayne Kalb
12 May 23
3
Michael Wayne Kalb
12 May 23
144
Notice of proposed sale of securities
12 May 23
4
Darren S Cline
14 Apr 23
3
Darren S Cline
13 Apr 23
3
Rajiv Amin
10 Mar 23
4
Leonard Paolillo
16 Feb 23
4
John Hoekman
16 Feb 23
4
John Harold Leaman
16 Feb 23
4
ADRIAN ADAMS
16 Feb 23
4
John Harold Leaman
4 Jan 23
4
Diane E. Wilfong
17 Jun 22
4
MAHENDRA SHAH
17 Jun 22
4
TIMOTHY S NELSON
17 Jun 22
4
H STEWART PARKER
17 Jun 22
4
David D. Allison
17 Jun 22
4
STEPHEN B SHREWSBURY
30 Mar 22
4
STEPHEN B SHREWSBURY
28 Jan 22
4
Leonard Paolillo
28 Jan 22
4
John Harold Leaman
28 Jan 22